Oxidative stress‐driven metabolic reprogramming defines two subtypes of cutaneous melanoma
- 1Department of Human Cell Biology and Genetics, SUSTech Homeostatic Medicine Institute, School of Medicine Southern University of Science and Technology Shenzhen China
Abstract
The high heterogeneity of skin cutaneous melanoma (SKCM) remains a major obstacle to effective personalized treatment. Existing classification methods may not fully capture the molecular characteristics dictated by the extensive metabolic reprogramming, limiting treatment options. While existing classifications focus on driver mutations, they often overlook the metabolic plasticity due to changes in physicochemical conditions in the cancer microenvironments that facilitate therapeutic resistance. This study aimed to identify novel, metabolism‐centric molecular subtypes of SKCM samples to explore potential clinical vulnerabilities and investigate possible underlying mechanisms. We identified two distinct subtypes through unsupervised clustering based on multi‐omic data. The two subtypes were found to have distinct prognostic and biological drivers: the pro‐oxidative metabolic subtype (POMS) and the inflammation‐driven subtype (IMS). The POMS tends to have significantly worse survival than the IMS patients. Our integrative analyses support a computational prediction that POMS is associated with elevated oxidative‐stress‐related signatures, increased TMB, reduced immune‐related pathway activity, and hyperactive mTORC1 signaling, suggesting a stress‐adaptive metabolic state that warrants future experimental validation. The IMS relied on inflammatory signaling, such as the JAK‐STAT pathway. In silico predictions suggest that POMS exhibit increased sensitivity to Trametinib and Sorafenib, while IMS is sensitive to PLX4720, Rapamycin, Ruxolitinib, and Cisplatin. In retrospective public data, the classifier showed strong prognostic relevance beyond American Joint Committee on Cancer staging, while prospective validation on independent clinical samples is needed before clinical applications. Our study may inform future investigations into the treatment resistance of the disease.
Related
- Olaparib Blocks Oxidative Stress-Dependent NLRP3 Inflammasome in Pediatric Acute Lung Injury by Metabolic Reprogramming via AMPK-Driven Autophagic Flux.
- HDAC inhibition drives NOX5-dependent oxidative stress and sensitizes uveal melanoma cells to SOD1 inhibition
- Gangliosides in Cutaneous Melanoma: Molecular Mechanisms, Translational Evidence Gaps, and Preclinical Natural-Compound Leads
- Lipid droplet organized metabolic vulnerabilities in melanoma: from the MITF low state to ferroptosis sensitization
- Metabolic reprogramming and metabolic homeostasis in podocyte injury: novel mechanistic insights and natural product therapies
BibTeX
@article{gao2026oxidative,
title = {{Oxidative stress‐driven metabolic reprogramming defines two subtypes of cutaneous melanoma}},
author = {Qikun Gao and Ziyi Liu and Ying Xu},
journal = {View},
year = {2026},
month = oct,
doi = {10.1002/viw2.70183},
url = {https://doi.org/10.1002/viw2.70183},
note = {CC BY},
}
RIS
TY - JOUR
TI - Oxidative stress‐driven metabolic reprogramming defines two subtypes of cutaneous melanoma
AU - Qikun Gao
AU - Ziyi Liu
AU - Ying Xu
PY - 2026
DA - 2026/10/26
JO - View
DO - 10.1002/viw2.70183
UR - https://doi.org/10.1002/viw2.70183
AB - The high heterogeneity of skin cutaneous melanoma (SKCM) remains a major obstacle to effective personalized treatment. Existing classification methods may not fully capture the molecular characteristics dictated by the extensive metabolic reprogramming, limiting treatment options. While existing classifications focus on driver mutations, they often overlook the metabolic plasticity due to changes in physicochemical conditions in the cancer microenvironments that facilitate therapeutic resistance. This study aimed to identify novel, metabolism‐centric molecular subtypes of SKCM samples to explore potential clinical vulnerabilities and investigate possible underlying mechanisms. We identified two distinct subtypes through unsupervised clustering based on multi‐omic data. The two subtypes were found to have distinct prognostic and biological drivers: the pro‐oxidative metabolic subtype (POMS) and the inflammation‐driven subtype (IMS). The POMS tends to have significantly worse survival than the IMS patients. Our integrative analyses support a computational prediction that POMS is associated with elevated oxidative‐stress‐related signatures, increased TMB, reduced immune‐related pathway activity, and hyperactive mTORC1 signaling, suggesting a stress‐adaptive metabolic state that warrants future experimental validation. The IMS relied on inflammatory signaling, such as the JAK‐STAT pathway. In silico predictions suggest that POMS exhibit increased sensitivity to Trametinib and Sorafenib, while IMS is sensitive to PLX4720, Rapamycin, Ruxolitinib, and Cisplatin. In retrospective public data, the classifier showed strong prognostic relevance beyond American Joint Committee on Cancer staging, while prospective validation on independent clinical samples is needed before clinical applications. Our study may inform future investigations into the treatment resistance of the disease.
SN - 2688-268X
SN - 2688-3988
ER -